Chemotherapy Complications

Hospital Medicine Clinics

Volumn 5, Issue 3, 2016, Pages 400-412

  Campagna, Maria Claudia ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cardiotoxicity; Chemotherapy adverse effects; Myelosuppression; Nephrotoxicity; Neurotoxicity; Side effects management

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTACID AGENT; ANTIANEMIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; METOCLOPRAMIDE; NITROSOUREA DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PENICILLIN DERIVATIVE; PENTOSTATIN; TAMOXIFEN; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

ACUTE HEART FAILURE; ALLERGIC PNEUMONITIS; ANEMIA; ANGINA PECTORIS; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER PATIENT; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COGNITIVE DEFECT; DIARRHEA; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG GLUCURONIDATION; DRUG POTENTIATION; EPIGASTRIC PAIN; ERYTHROCYTE TRANSFUSION; ESOPHAGITIS; FIBROSING ALVEOLITIS; GASTROINTESTINAL DISEASE; HEART INFARCTION; HEMATOLOGIC DISEASE; HOSPITAL PATIENT; HUMAN; HYPOTENSION; INTERDISCIPLINARY COMMUNICATION; KIDNEY DISEASE; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; LUNG TOXICITY; MOOD DISORDER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; PATIENT MONITORING; PERICARDIAL EFFUSION; PERICARDITIS; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QT PROLONGATION; RAYNAUD PHENOMENON; REPRODUCTIVE TOXICITY; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; TACHYCARDIA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 84975496632     PISSN: 22115943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehmc.2016.02.001     Document Type: Review

References (35)

1. Lokeic F. Drug interactions and pharmacogenetics. Side effects of medical cancer therapy 2013, 1-28. Springer-Verlag, London. 1st edition. M.A. Dicato (Ed.).
2. Ettinger DS, Berger MJ. NCCN guidelines: antiemesis. 2015. Available at:. Accessed December 10, 2015. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
3. Roila F., Herrstedt J., Aapro M., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21(Suppl 5):v232-243.
4. Rubin K.M. Managing immune-related adverse events to ipilimumab: a nurse's guide (on-line exclusive). Clin J Oncol Nurs 2012, 16(2):E69-E75.
5. Keefe D.M., Schubert M.M., Elting L.S., et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007, 109(5):820-831.
6. Worthington H.V., Clarkson J.E., Bryan G., et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2011, (4). CD000978.
7. Camp-Sorell D. Chemotherapy toxicities and management. Cancer nursing: principles and practice 2011, 458-503. Jones and Bartlett, Burlington (MA). C.H. Yarbro, D. Wujcki, B. Holmes Gobel (Eds.).
8. Harmening D.M., Marty J., Strauss R.G. Cell biology, disorders of neutrophils, infectious mononucleosis, and reactive lymphocytosis. Clinical hematology and fundamentals of hemostasis 2009, 305-330. FA Davis, Philadelphia. 5th edition.
9. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Cancer and chemotherapy- induced anemia Version 1;2014.
10. Rodgers GM, Gilreath JA. NCCN guidelines: cancer-and chemotherapy-induced anemia. 2015. Available at:. Accessed December 10, 2015. http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf.
11. Hill S.R., Carless P.A., Henry D.A., et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2002, (2). CD002042.
12. Khorana A.A., Francis C.W., Blumberg N., et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008, 168(21):2377-2381.
13. Estcourt L.J., Stanworth S., Doree C., et al. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2014, (3). CD010983.
14. Slichter S.J. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007, 172-178.
15. Yusuf S.W., Razeghi P., Yeh E.T. The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol 2008, 33(4):163-196.
16. Barry E., Alvarez J.A., Scully R.E., et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007, 8(8):1039-1058.
17. van Dalen E.C., Caron H.N., Dickinson H.O., et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011, (6). CD003917.
18. Berardi R., Caramanti M., Savini A., et al. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol 2013, 88(1):75-86.
19. Schwaiblmair M., Behr W., Haeckel T., et al. Drug induced interstitial lung disease. Open Respir Med J 2012, 6:63-74.
20. Byrd RP, Roy TM. Drug-induced pulmonary toxicity. 2014. 2015. Available at:. Accessed December 10, 2015. http://emedicine.medscape.com/article/1343451-overview.
21. Aloia T.A., Fahy B.N. Chemotherapy-associated hepatotoxicity: how concerned should we be?. Expert Rev Anticancer Ther 2010, 10(4):521-527.
22. Verma S., Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009, 58(11):1555-1564.
23. Fleming J.N., Abou Abbass A. Hepatorenal syndrome: a comprehensive overview for the critical care nurse. Crit Care Nurs Clin North Am 2010, 22(3):351-368.
24. Wilkes G.M., Barton-Burke M. 2013 oncology nursing drug handbook 2013, Jones and Bartlett, Burlington (MA).
25. Perazella M.A., Moeckel G.W. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 2010, 30(6):570-581.
26. Bhadauria D., Agarwal N. Toxic acute kidney injury. Clinical Queries Nephrology 2012, 1(1):29-33.
27. Flombaum C.D. Nephrotoxicity of chemotherapy agents and chemotherapy administration in patients with renal disease. Cancer and the kidney: the frontier of nephrology and oncology 2011, 115-176. Oxford University Press, Oxford (United Kingdom). 2nd edition. E.P. Cohen (Ed.).
28. Hensley M.L., Hagerty K.L., Kewalramani T., et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009, 27(1):127-145.
29. Wolf S., Barton D., Kottschade L., et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44(11):1507-1515.
30. Argyriou A.A., Bruna J., Marmiroli P., et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012, 82(1):51-77.
31. Gamelin E., Gamelin L., Bossi L., et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002, 29(5 Suppl 15):21-33.
32. Loprinzi C.L., Qin R., Dakhil S.R., et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 2014, 32(10):997-1005.
33. Brewer J.R., Morrison G., Dolan M.E., et al. Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol 2016, 140(1):176-183.
34. Marmiroli P., Cavaletti G. Drugs for the treatment of peripheral neuropathies. Expert Opin Pharmacother 2016, 17(3):381-394.
35. Lezak M.D., Howieson D.B., Bigler E.D., et al. Neuropsychological assessment 2012, Oxford University Press, New York.